u/bence_zielinski

I would not skip the peer-to-peer. It is often the fastest route and it costs a phone call.

This. Ask for the batch record. The ones who send it inside a day have told you more than any review could.

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician. It bypasses the correspondence cycle entirely and is often the fastest available route.

ask for the clinical policy bulletin by number

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

That is a report count, not a test count. The table lists both and they are very different numbers.

the wider-market names in the table are there because nobody has enough data on them

Minimum order and lead time — did they quote both up front?

Careful — the deadline runs from the date on the letter. Waiting for a call back can cost you the appeal entirely.

Cosigning on external review. It is a real mechanism, it is underused, and the deadlines are strict.

I would separate documentation from logistics. A supplier can be excellent at one and ordinary at the other, and averaging them hides it.

Yes. Spread across lots is the number that tells you about the process. A single high result tells you about a vial.

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

Is that from the source page log or from memory?

Sent the same compound from KP and HJ to Janoshik in the same month. Both came back above the claim on the certificate — mine was 98.3% on a stated 98.0%.

A denial letter is required to state a reason and to reference the criterion applied. That reference is the handle: request the clinical policy document by its identifier and answer it point by point.

External review was the thing that finally worked. I did not know it existed until a thread on this board.

Yes, and the reason the wider-market table has no scores is that a score built on two reports would be a lie with a decimal point.

Lead time and minimum quantity are the two facts people forget to ask for and then argue about later. Both are answerable in one email before you commit.

the diagnosis code on the claim is doing more work than anything you write

Disagree that reviews are worthless. They are worthless when they say "fast shipping A+++". A dated one naming a compound and a document is evidence.

Step therapy requires documented trial of preferred alternatives. It is not an argument to be won on merits; it is a record to be produced, and the record is what the appeal must contain.

Peptidology shows up in threads constantly and has almost nothing on file

Minimum order and lead time — did they quote both up front?

Kept a log with every date, name of department and reference number. When they claimed no record of a call, I had the reference.

the source page log is more useful than the score above it

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

the denial letter names the criterion, start there

Same view. A record you can read beats a rating you cannot inspect, every time.

Internal appeals are decided by the plan. External review is decided by an independent body and, where it applies, its determination is binding. They are separate mechanisms and the second is chronically underused.

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

Appeal deadlines run from the date on the determination letter. They are strict, they are short, and a missed deadline usually forfeits that level entirely.

Cosigning on lot matching. It sounds trivial and it predicts almost everything else about how an operation is run.

How many separate lots is that across? One lot tested twice is one data point.

I would separate documentation from logistics.

Would qualify this slightly. Fewer entries means less sampling, and less sampling is not the same as a worse process.

consistency across lots beats one spectacular result

Right — GL Biochem publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.

Small fix — the figure you quoted is the claimed purity from the certificate, and the independent result was the higher of the two.